bioAffinity Technologies, Inc. (BIAFW) Stock Analysis and Metrics

bioAffinity Technologies

NASDAQ: BIAFW

$0.10 ▲ +0.00 (+0.00%)

At close: Jul 9, 2026 · 4:00 PM UTC

Financial Ratios

Total Debt (Qtr)38,915.00

Revenue Growth (1y) (Qtr)-27.09

Add ratio to table…

About

bioAffinity Technologies develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis informed by machine learning. The company's primary commercial product is CyPath® Lung, which identifies and analyzes cell populations in sputum to indicate malignancy in the lung. CyPath® Lung is performed by the company's wholly owned subsidiary PPLS, a CAP-accredited and CLIA-certified clinical anatomic and pathology laboratory that has operated for more than 18 years.

The company generates revenue primarily through the sale of CyPath® Lung tests to physicians who order the test to assist in assessing patients at high risk for lung cancer. Revenue is also derived from ongoing development of companion diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD) using the same flow cytometry and AI platform. Additional revenue comes from research collaborations, including those with Brooke Army Medical Center, focused on expanding the utility of bronchoscopy-collected samples for earlier lung cancer detection.

The company operates through the following segments:

• CyPath® Lung: This segment focuses on the commercialization and delivery of the company's first diagnostic test for early-stage lung cancer detection. CyPath® Lung uses flow cytometry and artificial intelligence to analyze sputum samples for cancer and cancer-related cells. The test provides a physician’s report within three days of sample arrival, stratifying patients into risk categories based on a numerical probability score.

• Companion Diagnostics for Asthma and COPD: This segment involves the development of diagnostic tools to quantify lung inflammation and identify patients likely to benefit from specific biologic therapies. Research in this area aims to match patients with effective treatments and monitor disease progression using sputum analysis. The segment leverages the company's flow cytometry platform with AI analysis to detect therapeutic targets such as receptors for dupilumab and benralizumab.

• OncoSelect® Therapeutics: This segment conducts research on novel cancer therapeutic approaches that selectively target cancer cells. Work includes the development of topical treatments for squamous cell skin cancer based on discoveries involving the synthetic porphyrin TCPP. The company intends to seek strategic partners to advance these findings toward broad-spectrum cancer treatments. Research is conducted in laboratories at PPLS and through collaborations with academic institutions.

bioAffinity Technologies operates in the competitive lung cancer diagnostics market, where it positions itself as a provider of noninvasive, cost-effective tests with high sensitivity and specificity. The company's CyPath® Lung test demonstrates 92% sensitivity and 87% specificity for nodules under 20 mm, outperforming several competitors in balance and accuracy. Competitors include LungLB by LungLife AI, Nodify XL2 and Nodify CDT by Biodesix, and the Percepta nasal swab test by Veracyte, all of which show lower performance in key metrics or limitations in usability across patient populations.

The company serves physicians who order diagnostic tests for patients at high risk of lung cancer, particularly those with indeterminate pulmonary nodules detected by CT imaging. Specific customers include Brooke Army Medical Center, Walter Reed Medical Center, and the South Texas Audie L. Murphy Memorial Veterans Medical Center, which participate in clinical trials and research collaborations. The company also works with healthcare providers in academic, military, and VA medical centers to advance adoption of its diagnostic technology.

Investment Thesis

▲ Bull case

bioAffinity Technologies is positioned to capture significant growth in the lung cancer diagnostics market, which is projected to reach $10.4 billion by 2034 at an 8.1% compound annual growth rate, with the company's CyPath® Lung test demonstrating strong clinical performance including 92% sensitivity, 87% specificity, and 99% negative predictive value in high-risk patients with indeterminate nodules under 20mm. The test's high NPV provides physicians with confidence to avoid unnecessary invasive procedures, directly addressing a critical pain point in clinical workflow where indeterminate pulmonary nodules are projected to grow 62% from 2.9 million in 2025 to 4.7 million by 2030, creating a substantial addressable market for non-invasive risk stratification tools. The company's recent Q1 2026 financial results show revenue of $1.4 million, with unit sales growing 146% year-over-year in Q1 2026 and achieving record monthly growth of nearly 300% in April 2026 compared to the prior year, indicating accelerating commercial traction that exceeds internal projections and reflects growing physician adoption despite the company's early commercialization stage.
The company's strategic expansion beyond lung cancer diagnostics into adjacent respiratory disease markets represents a significant underestimated catalyst, particularly through its Brooke Army Medical Center collaboration to validate CyPath® Lung's use with deep suction samples from bronchial and tracheal procedures, which could unlock access to the approximately 500,000 annual bronchoscopy procedures in the U.S. market valued at $700–$920 million. Concurrently, bioAffinity's development of inflammatory biomarker tests for asthma and COPD using its proprietary flow cytometry+AI platform targets a global market affecting 650 million people, with the potential to shift management toward precision medicine by matching patients to effective biologic therapies like dupilumab and benralizumab, thereby diversifying revenue streams and reducing reliance on a single product while leveraging existing technological infrastructure.
bioAffinity Technologies has strengthened its competitive moat through robust global intellectual property protection, recently receiving allowance for a Mexican patent covering the core CyPath® Lung methodology involving defined antibodies and porphyrin TCPP labeling via flow cytometry, which now joins existing patents in the U.S., EU, China, Japan, Australia, and Canada, creating comprehensive international coverage that safeguards its proprietary technology against replication and supports long-term value creation. This IP expansion is reinforced by the company's Precision Pathology Laboratory Services subsidiary maintaining College of American Pathologists (CAP) accreditation—the gold standard in lab quality—ensuring reliability and trust from healthcare providers, which is critical for LDT adoption and reimbursement negotiations, while the company's leadership emphasizes that strong IP directly benefits shareholders by protecting commercialization efforts in a market where diagnostic accuracy and regulatory compliance are paramount.

bioAffinity Technologies is positioned to capture significant growth in the lung cancer diagnostics market, which is projected to reach $10.4 billion by 2034 at an 8.1% compound annual growth rate, with the company's CyPath® Lung test demonstrating strong clinical performance including 92% sensitivity, 87% specificity, and 99% negative predictive value in high-risk patients with indeterminate nodules under 20mm. The test's high NPV provides physicians with confidence to avoid unnecessary invasive procedures, directly addressing a critical pain point in clinical workflow where indeterminate pulmonary nodules are projected to grow 62% from 2.9 million in 2025 to 4.7 million by 2030, creating a substantial addressable market for non-invasive risk stratification tools. The company's recent Q1 2026 financial results show revenue of $1.4 million, with unit sales growing 146% year-over-year in Q1 2026 and achieving record monthly growth of nearly 300% in April 2026 compared to the prior year, indicating accelerating commercial traction that exceeds internal projections and reflects growing physician adoption despite the company's early commercialization stage.
The company's strategic expansion beyond lung cancer diagnostics into adjacent respiratory disease markets represents a significant underestimated catalyst, particularly through its Brooke Army Medical Center collaboration to validate CyPath® Lung's use with deep suction samples from bronchial and tracheal procedures, which could unlock access to the approximately 500,000 annual bronchoscopy procedures in the U.S. market valued at $700–$920 million. Concurrently, bioAffinity's development of inflammatory biomarker tests for asthma and COPD using its proprietary flow cytometry+AI platform targets a global market affecting 650 million people, with the potential to shift management toward precision medicine by matching patients to effective biologic therapies like dupilumab and benralizumab, thereby diversifying revenue streams and reducing reliance on a single product while leveraging existing technological infrastructure.
bioAffinity Technologies has strengthened its competitive moat through robust global intellectual property protection, recently receiving allowance for a Mexican patent covering the core CyPath® Lung methodology involving defined antibodies and porphyrin TCPP labeling via flow cytometry, which now joins existing patents in the U.S., EU, China, Japan, Australia, and Canada, creating comprehensive international coverage that safeguards its proprietary technology against replication and supports long-term value creation. This IP expansion is reinforced by the company's Precision Pathology Laboratory Services subsidiary maintaining College of American Pathologists (CAP) accreditation—the gold standard in lab quality—ensuring reliability and trust from healthcare providers, which is critical for LDT adoption and reimbursement negotiations, while the company's leadership emphasizes that strong IP directly benefits shareholders by protecting commercialization efforts in a market where diagnostic accuracy and regulatory compliance are paramount.

▼ Bear case

bioAffinity Technologies faces significant financial headwinds that the market may be underestimating, as evidenced by its Q1 2026 financial results showing a net loss of $3.6 million ($0.81 per share) on $1.35 million in revenue, representing a worsening loss trajectory compared to Q1 2025's $2.7 million loss on $1.85 million revenue, despite claims of accelerating unit sales growth; this divergence suggests either declining average selling prices, increasing costs per test, or that revenue recognition lags behind unit volumes, raising concerns about the sustainability of its commercialization model and the company's ability to achieve profitability given its limited operating history and accumulated deficit of over $72 million as of March 31, 2026.
The company's overwhelming dependence on its single commercial product, CyPath® Lung, creates substantial execution risk, particularly as it navigates the uncertain regulatory environment for Laboratory Developed Tests (LDTs), where potential increased FDA oversight could impose costly validation requirements, delay market access, or necessitate expensive 510(k) submissions or PMA applications that the company may lack the capital to fund, especially given its Q1 2026 cash position of only $3.1 million—down from $6.4 million at year-end 2025—and its stated need for additional financing to fund operations, which could lead to dilutive equity offerings or restrictive debt terms if external capital is required.
Reimbursement uncertainty remains a critical unaddressed hurdle, as CyPath® Lung's adoption and scalability depend heavily on third-party payer coverage, yet the company provides no concrete progress on securing broad reimbursement contracts despite highlighting its value in reducing unnecessary procedures; without reliable reimbursement, physician adoption may remain limited to self-pay or research settings, constraining revenue growth potential, especially since the company's forward-looking statements explicitly cite "the Company's ability to obtain and maintain adequate reimbursement from third-party payors" as a key risk, and its current business model as an LDT may face tighter scrutiny under evolving CLIA regulations, potentially undermining its cost advantage over traditional diagnostic pathways.

bioAffinity Technologies faces significant financial headwinds that the market may be underestimating, as evidenced by its Q1 2026 financial results showing a net loss of $3.6 million ($0.81 per share) on $1.35 million in revenue, representing a worsening loss trajectory compared to Q1 2025's $2.7 million loss on $1.85 million revenue, despite claims of accelerating unit sales growth; this divergence suggests either declining average selling prices, increasing costs per test, or that revenue recognition lags behind unit volumes, raising concerns about the sustainability of its commercialization model and the company's ability to achieve profitability given its limited operating history and accumulated deficit of over $72 million as of March 31, 2026.
The company's overwhelming dependence on its single commercial product, CyPath® Lung, creates substantial execution risk, particularly as it navigates the uncertain regulatory environment for Laboratory Developed Tests (LDTs), where potential increased FDA oversight could impose costly validation requirements, delay market access, or necessitate expensive 510(k) submissions or PMA applications that the company may lack the capital to fund, especially given its Q1 2026 cash position of only $3.1 million—down from $6.4 million at year-end 2025—and its stated need for additional financing to fund operations, which could lead to dilutive equity offerings or restrictive debt terms if external capital is required.
Reimbursement uncertainty remains a critical unaddressed hurdle, as CyPath® Lung's adoption and scalability depend heavily on third-party payer coverage, yet the company provides no concrete progress on securing broad reimbursement contracts despite highlighting its value in reducing unnecessary procedures; without reliable reimbursement, physician adoption may remain limited to self-pay or research settings, constraining revenue growth potential, especially since the company's forward-looking statements explicitly cite "the Company's ability to obtain and maintain adequate reimbursement from third-party payors" as a key risk, and its current business model as an LDT may face tighter scrutiny under evolving CLIA regulations, potentially undermining its cost advantage over traditional diagnostic pathways.

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password